Is Acutus Medical a Winning Medical Device Stock?

: AFIB | Acutus Medical Inc. News, Ratings, and Charts

AFIB – Arrhythmia management company Acutus Medical (AFIB) recently announced it had received a commitment letter from Deerfield Management Company to refinance its existing debt with a new longer-term credit facility. The news pushed its share price higher. However, considering the bearish analysts’ sentiments around the company’s near-term prospects, would it be wise to bet on AFIB now? Read on to learn our view.

Arrhythmia management company Acutus Medical, Inc. (AFIB - Get Rating) in Carlsbad, Calif., designs, manufactures and markets a range of tools for catheter-based ablation procedures to treat various arrhythmias in the United States and internationally. AFIB shares have slumped 91.4% in price over the past year and 67.7% year-to-date to close yesterday’s trading session at $1.10.

The stock gained traction last week after the company announced that it had secured a commitment letter from Deerfield Management Company to refinance its existing debt with a new longer-term credit facility. AFIB also announced a definitive agreement to sell its left-heart access portfolio to Medtronic Plc (MDT). 

The company expects these two transactions and its recently completed restructuring to result in a comprehensive recapitalization of the business to fund its strategic growth priorities. AFIB stock has been up 1.4% in price over the past five days.

Here is what could shape AFIB’s performance in the near term:

Poor Profitability

AFIB’s negative 90.73% gross profit margin is substantially lower than the 55.18% industry average.

Furthermore, AFIB’s negative 101.32%, 69.31%, and 45.43% respective ROE, ROA, and ROT compare with the negative 37.46%, 24.85%, and 19.97% industry averages.

Weak Bottom Line

The company’s revenue increased 69.5% year-over-year to $4.36 million in its fiscal fourth quarter, ended Dec. 31, 2021. Its loss from operations stood at $29.90 million, up 6.8% from its year-ago value. AFIB’s net loss increased 6.3% year-over-year to $31.26 million, while its comprehensive loss grew 7.7% year-over-year to $31.44 million. Its net loss per share increased 6.7% from the prior-year quarter to $1.12. And on a non-GAAP basis, its net loss for the fourth quarter of 2021 was $27.99 million, or $1.00 per share, compared to $24.86 million, or $0.89 per share, for the fourth quarter of 2020. Also, its cash and cash equivalents balance came in at $24.22 million in its fiscal year ended Dec. 31, 2021, indicating a 4.6% decline year-over-year.

Bearish Sentiments

Analysts have reduced their revenue estimate for this year to $17 million versus the previous estimate of $23 million. Also, analysts now expect AFIB’s loss per share for the fiscal year to be  $3.01, compared to the earlier expectation of $2.83. Also, its sales are expected to reverse, with a forecast 1.3% annualized revenue decline through the end of 2022, compared to its historical growth of 67% over the last three years. In addition, AFIB is expected to perform substantially worse than the wider industry.

The Street expects AFIB’s revenue to decline 12.9% year-over-year to $3.13 million in the about to be reported quarter, ended March 31, 2022. Also, its revenue is expected to decrease 18.2% in the current  quarter, ending June 30, 2022, 5.5% in the next quarter, ending Sept. 30,  2022, and 3.9% in the current fiscal year. Also, the company’s EPS is expected to remain negative at least until this year.

POWR Ratings Reflect This Bleak Prospects

AFIB has an overall D rating, which translates to Sell in our proprietary POWR Ratings system. The POWR Ratings are calculated by considering 118 distinct factors, with each factor weighted to an optimal degree.

The stock has an F grade for Quality, which is consistent with its negative profit margins.

AFIB has a D grade for Sentiment. Bearish analysts’ sentiments about the stock justify this grade.

Of the 157 stocks in the D-rated  Medical – Devices & Equipment industry, AFIB is ranked #131.

Beyond what I have stated above, one can also view AFIB’s grades for Stability, Growth, Momentum, and Value here.

View the top-rated stocks in the Medical – Devices & Equipment industry here.

Click here to checkout our Healthcare Sector Report for 2022

Bottom Line

Although the company posted significant revenue growth in its last reported quarter, analysts are bearish about its near-term topline performance. Also, analysts increased their loss per share estimates for this year. So, given its bleak financial positioning, I think it could be wise to avoid the stock for now.

How Does Acutus Medical, Inc. (AFIB) Stack Up Against its Peers?

While AFIB has an overall POWR Rating of D, one might want to consider investing in the following Medical – Devices & Equipment stocks with an A (Strong Buy) rating: Fonar Corporation (FONR - Get Rating), Abbott Laboratories (ABT - Get Rating), and Electromed, Inc. (ELMD - Get Rating).

Want More Great Investing Ideas?

3 Stocks to DOUBLE This Year


AFIB shares fell $0.01 (-0.91%) in premarket trading Wednesday. Year-to-date, AFIB has declined -67.74%, versus a -12.06% rise in the benchmark S&P 500 index during the same period.


About the Author: Subhasree Kar


Subhasree’s keen interest in financial instruments led her to pursue a career as an investment analyst. After earning a Master’s degree in Economics, she gained knowledge of equity research and portfolio management at Finlatics. More...


More Resources for the Stocks in this Article

TickerPOWR RatingIndustry RankRank in Industry
AFIBGet RatingGet RatingGet Rating
FONRGet RatingGet RatingGet Rating
ABTGet RatingGet RatingGet Rating
ELMDGet RatingGet RatingGet Rating

Most Popular Stories on StockNews.com


Why is Stock Market Outlook So Uncertain?

The S&P 500 (SPY) has quickly pushed back from the highs and once again on the verge of a break below the 100 day moving average. Why is this happening? And what comes next? 40 year investment veteran Steve Reitmeister shares his view and top stocks in the commentary that follows...

3 Under-the-Radar Tech Stocks Quietly Powering the Digital Revolution

The technology industry's future seems promising, owing to increasing investments and rising worldwide demand for better products. Hence, investing in fundamentally stable tech stocks, Motorola (MSI), Power Integrations (POWI), and CI&T (CINT) could be the move for investors looking to capitalize on the sector's growth. Read on…

3 AI-Powered Drug Discovery Stocks Revolutionizing Medicine

The pharmaceutical industry is evolving continuously with the advancements in drug discovery with Artificial Intelligence (AI), propelling the industry’s growth. Amid this backdrop, quality medical stocks Pfizer (PFE), AstraZeneca (AZN), and Novartis (NVS), which are transforming medicine with AI-powered drug discovery, could be ideal portfolio additions. Continue reading...

3 Metaverse Stocks Building the Virtual Economy

The metaverse isn’t just a futuristic fantasy; it’s shaping up to be the next big digital economy. As digital spaces evolve into thriving marketplaces, companies like Apple (AAPL), NVIDIA Corp. (NVDA), and Meta Platforms (META) are building the foundation for this new era. Thus, investing in them could be rewarding. Read more…

Trump or the Fed More Important to Stock Investors?

The S&P 500 (SPY) is flirting with new highs once again. But it is not very clear what is driving these stock price gains. That is why Steve Reitmeister shares his latest views including a market outlook, trading plan and top picks to stay on the right side of the action.

Read More Stories

More Acutus Medical Inc. (AFIB) News View All

Event/Date Symbol News Detail Start Price End Price Change POWR Rating
Loading, please wait...
View All AFIB News